Medical guidelines now advise against taking aspirin daily to prevent heart disease in people over 70, because the risk of bleeding is too high; for those between 60 and 70, the decision should be made individually with a doctor.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review evaluating the balance of benefits and harms of aspirin for primary prevention in adults ≥70 to inform guideline development.
A systematic review and meta-analysis of all RCTs and cohort studies on aspirin for primary prevention in adults ≥70, with GRADE assessment of cardiovascular benefit, bleeding harm, cancer outcomes, and quality of life, used to inform formal guideline recommendations by USPSTF or AHA/ACC.
A cohort study can assess whether guideline-adherent aspirin use patterns correlate with improved outcomes in elderly populations.
A prospective cohort study of 12,000 adults aged 65–80 comparing outcomes in those who followed vs. deviated from USPSTF aspirin guidelines, with outcomes including bleeding, CVD events, and mortality, adjusting for socioeconomic and healthcare access factors.
A case-control study can assess whether guideline non-adherence is associated with adverse outcomes in elderly patients with high CVD risk.
A matched case-control study comparing 800 elderly patients with major bleeding or CVD events to 1,600 matched controls, assessing prior adherence to USPSTF aspirin guidelines via medical records and pharmacy data.
A cross-sectional survey can estimate the prevalence of aspirin use in elderly populations relative to current guidelines.
A nationally representative cross-sectional survey of 15,000 U.S. adults aged 60–80 assessing current aspirin use, awareness of guidelines, and clinician discussion, stratified by age group and CVD risk.
An expert opinion can summarize rationale for guideline changes but cannot generate evidence for them.
An editorial or commentary by guideline panel members explaining the rationale for updating aspirin recommendations based on emerging evidence.